Sanofi

Sanofi received a positive recommendation from the European Union===European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for its drug Rezurock, which is a significant step towards market authorization in the EU. This could lead to increased revenue and market share for Sanofi in the treatment of chronic graft-versus-host disease (GVHD).

Sanofi's Board of Directors appointed Belén Garijo as the new Chief Executive Officer, replacing Paul Hudson. This leadership change is expected to bring increased rigor to strategy implementation and accelerate future preparations, focusing on productivity, governance, and R&D innovation.

Sanofi is expanding its Global Capability Centre (GCC) in India===Hyderabad, India, with a multi-hundred-million investment and an increase in workforce to over 4,500 employees. This expansion will support critical processes across drug research, development, manufacturing, and access lifecycle, leveraging India's talent pool in digital innovation, AI, and data science.

Sanofi's Board of Directors is proposing new appointments and renewals, aiming to strengthen its governance with diverse expertise, particularly with the addition of Christel Heydemann. This move is expected to support Sanofi's future development and strategic vision.

Sanofi has updated its total number of voting rights and shares, a routine disclosure for publicly traded companies. This information is important for investors to understand the company's capital structure.